A5 Laboratories Inc.
OTC Bulletin Board : AFLB

A5 Laboratories Inc.

February 03, 2011 14:23 ET

A5 Laboratories Has Received Approval Letter for It's Containment Level 2 Facility

MONTREAL, QUEBEC--(Marketwire - Feb. 3, 2011) - A5 Laboratories Inc. (A5 Labs) (OTCBB:AFLB) announced today the office of Biohazard and Containment Safety in their letter dated February 1, received on February 2 stated the office has received and reviewed the inspection checklist for the animal Pathogen Containment Level 2 at our facility in Lachine and found them acceptable for work in vitro. We will be waiting for another approval from the authorities before being able to work in pathogen agent at our laboratories. This is pathogen like E.Coli, and some other bacteria will be needed to be used as standard in our CRO laboratories.

This is important news for us toward our capacity of performing tests and analysis in-house stated Richard Azani, president and CEO of A5 Laboratories.

More information about the Company is available at its corporate website at www.a5labs.com

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • A5 Laboratories Inc.
    Richard Azani, Ph.D.
    President & C.E.O.
    514-420-0333